Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bushu Aims to Become No. 1 Contract Drug Maker in Japan
July 24, 2006
- Astellas to Promote Vesicare as 1st Choice OAB Treatment
July 24, 2006
- SUEVEY
July 24, 2006
- Teijin Pharma to Focus on New Drug Development in the US, Europe
July 24, 2006
- PII Study on Implanted Cardiac Assist Device Initiated
July 24, 2006
- Torrent Seeks Alliances with Japanese Companies
July 24, 2006
- Annual NHI Price Revision Would Cause Confusion: Mr Henmi of Nichibyokyo
July 24, 2006
- Sysmex America Receives Premier Pinnacle Award
July 24, 2006
- Chuikyo Discusses Frequency of NHI Drug Price Revisions
July 24, 2006
- SEMINAR
July 24, 2006
- Basic Policies 2006 Call For Enhancement of Drug Industry's Int'l Competitiveness
July 24, 2006
- SELF-MEDICATION NEWS IN BRIEF
July 24, 2006
- NEW PRODUCTS
July 24, 2006
- NEW PRODUCTS
July 24, 2006
- GENERIC NEWS IN BRIEF
July 24, 2006
- Drug Development Beyond Boundaries - Today's Global Cooperative Clinical Trials -
July 24, 2006
- Marketing Companies Must Ally to Survive: Mr Eguchi
July 17, 2006
- Japan Exchanges Opinions with Chinese Regulatory Authorities
July 17, 2006
- Ain Pharmaciez Sets Up Generic Drug Wholesaler
July 17, 2006
- REGULATORY NEWS IN BRIEF
July 17, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…